Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

University of Oklahoma researchers have created a new drug delivery system that helps cancer cells take in much more of a treatment, improving its ability to kill tumors. The findings are published in ...

A new study shows that lipid nanoparticles restructure their membrane significantly after being absorbed into a cell and ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...

If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent ...

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks as President Donald Trump listens at an event to promote his proposal to improve Americans' access to their medical records in the East ...

What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value ...